Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Pharmacogenomic Biomarker Study in Matched Patients With Severe Sepsis Treated With or Without Recombinant Human Activated Protein C [Xigris®, Drotrecogin Alfa (Activated)]

NCT01486524 is registered in ClinicalTrials.gov with Sirius Genomics Inc. as lead sponsor.

NCT NCT01486524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01486524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Pharmacogenomic Biomarker Study in Matched Patients With Severe Sepsis Treated With or Without Recombinant Human Activated Protein C [Xigris®, Drotrecogin Alfa (Activated)]
Lead sponsor
Sirius Genomics Inc.
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2011
Completion date
April 30, 2012
Enrollment
3,000 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock, severe sepsis